Streetbeat News

NSPR

InspireMD, Inc.

https://www.inspiremd.com

Industry

Medical - Devices

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Open

2.56

Mkt cap

67M

Volume

7.7K

High

2.63

P/E Ratio

-3.59

52-wk high

3.42

Low

2.55

Div yield

N/A

52-wk low

1.81

InspireMD announced that an abstract of one-year follow-up results from its C-GUARDIANS U.S. Investigational Device Exemption clinical trial has been accepted for presentation at LINC 2024. This development could indicate positive progress in their clinical trials and potential for future growth.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:14 am

InspireMD reported Q4 earnings with EPS of $(0.16), surpassing the $(0.20) estimate, and sales of $1.76M, exceeding the $1.63M estimate. This represents significant improvements over the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:01 pm

Numerous companies are scheduled to report their earnings on March 6, 2024, covering a wide range of industries from technology to retail. Notable mentions include JD.com with expected earnings of $0.63 per share on a revenue of $42.16 billion, and Abercrombie & Fitch forecasting $2.83 per share on $1.43 billion revenue. Other companies like Foot Locker, Thor Industries, and Campbell Soup are also set to report their earnings, alongside firms expected to report losses such as WAVE Life Sciences and EVgo.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 10:00 am

InspireMD (NASDAQ:NSPR) is scheduled to release its quarterly earnings report on March 6, 2024, with an estimated EPS of $-0.19. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows mixed reactions to past earnings, with the stock price fluctuating based on actual EPS versus estimates. Shares have risen 126.76% over the last 52 weeks, indicating a positive outlook among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 7:02 pm

InspireMD has announced the appointment of principal investigators for the C-GUARDIANS II clinical trial of its SwitchGuard Neuroprotection System. This step marks a significant advancement in the trial process, potentially impacting the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 12:05 pm

InspireMD, a medical device company, has received CE Mark recertification under the new Medical Device Regulation (MDR) framework of the European Union. This recertification is a significant regulatory milestone that allows the company to continue marketing and selling its products in the EU market.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 12:06 pm

InspireMD has announced the issuance of a key U.S. patent for its SwitchGuard Neuroprotection System, which is designed to protect against embolic events during stenting procedures. This patent strengthens the company's intellectual property portfolio and may enhance its competitive position in the market for neuroprotection devices.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:02 pm

InspireMD reported a sales increase for its CGuard EPS Stent Systems in Q3, selling 2,734 units compared to 2,624 units a year ago.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:06 pm

InspireMD reported Q3 losses of $(0.15) per share, in line with analyst consensus. This is a 74.14% increase over losses from the same period last year. The company's quarterly sales of $1.56 million beat the analyst consensus estimate of $1.50 million by 3.73%, marking an 8.74% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:04 pm

InspireMD (NASDAQ:NSPR) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $-0.15. The company's past performance shows a pattern of beating EPS estimates. The stock price, however, does not always correlate with earnings beats or misses, but often with the company's guidance. Shares of InspireMD are currently trading at $3.34 and have seen a 213.89% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.